Literature DB >> 15167283

Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins.

François Gimenez1, Christine Fernandez, Aloïse Mabondzo.   

Abstract

HIV protease inhibitors (HPIs) have limited penetration into the brain. This poor transport through the blood-brain barrier is mainly due to active efflux by proteins such as P-glycoprotein (P-gp) preventing drugs from clearing the brain of the virus. The present paper focuses on cerebral uptake of HPIs and interactions between HPIs and efflux proteins, either as substrates or modulators. Most of the studies described HPIs as P-gp substrates. Studies are more controversial when investigating HPIs as inhibitors of P-gp. HPIs seem to be able to inhibit efflux proteins of in vitro cell models but with limited consequences in vivo. Moreover, after repeated administrations of HPIs, most of them are also able to induce the expression and functionality of P-gp. For these reasons, certain combinations of HPIs may not efficiently increase brain uptake of HPIs as would combinations of more potent efflux inhibitors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15167283     DOI: 10.1097/00126334-200406010-00001

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  27 in total

1.  Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.

Authors:  Grégoire Dirson; Christine Fernandez; Patrick Hindlet; Françoise Roux; Michèle German-Fattal; François Gimenez; Robert Farinotti
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

2.  Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers.

Authors:  Hilda A Namanja; Dana Emmert; David A Davis; Christopher Campos; David S Miller; Christine A Hrycyna; Jean Chmielewski
Journal:  J Am Chem Soc       Date:  2011-09-09       Impact factor: 15.419

Review 3.  ABC drug transporter at the blood-brain barrier: effects on drug metabolism and drug response.

Authors:  Martin Ebinger; Manfred Uhr
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

Review 4.  CSF penetration by antiretroviral drugs.

Authors:  Christine Eisfeld; Doris Reichelt; Stefan Evers; Ingo Husstedt
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

5.  Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS.

Authors:  Lipa K Shah; Mansoor M Amiji
Journal:  Pharm Res       Date:  2006-09-13       Impact factor: 4.200

6.  Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier.

Authors:  Corbin J Bachmeier; Timothy J Spitzenberger; William F Elmquist; Donald W Miller
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

7.  Potent and Selective Inhibition of Plasma Membrane Monoamine Transporter by HIV Protease Inhibitors.

Authors:  Haichuan Duan; Tao Hu; Robert S Foti; Yongmei Pan; Peter W Swaan; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2015-08-18       Impact factor: 3.922

8.  Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor.

Authors:  Sheetal Agarwal; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2007-03-06       Impact factor: 5.875

9.  The antiretroviral protease inhibitor ritonavir accelerates glutathione export from cultured primary astrocytes.

Authors:  Christian Arend; Maria Brandmann; Ralf Dringen
Journal:  Neurochem Res       Date:  2013-01-23       Impact factor: 3.996

Review 10.  Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.

Authors:  Lucette A Cysique; Bruce J Brew
Journal:  Neuropsychol Rev       Date:  2009-05-09       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.